Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering
novel cancer therapies and dedicated to the discovery, development, and commercialization
of novel first-in-class drugs directed against nuclear export and related targets for the
treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear
Export (SINE) compounds function by binding with and inhibiting the nuclear export protein
XPO1. The company was founded in 2008 with a vision of pioneering a potentially new
approach to treating patients with certain blood cancers.
Brands: https://events.jspargo.com/ASCO21/CUSTOM/KPTI-logo_Blue-duotone_1140x250.jpg
Show Specials
Press Releases
Products